Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.

doi:10.1111/all.15940

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.

Allergy - 1 Mar 2024

Jimenez-Rodriguez Teodorikez-Wilfox, de Las Vecillas Leticia, Labella Marina, Lynch Donna-Marie, Besz Kylie Marie, Marquis Kathleen, Burgos Amparo, Soriano Gomis Victor, Lozano Inmaculada, Antón Rosa Ana Montoyo, de la Calle Francisco Marco, González Delgado María Purificación, Gutiérrez Aurora, Montenegro Estefanía, Rodríguez Fernando, Fernández Sánchez Francisco Javier, Castells Mariana

Abstract excerpt

BACKGROUND: Drug hypersensitivity reactions (DHRs) to platinum-based drugs are heterogenous and restrict their access, and drug desensitization (DD) has provided a ground-breaking procedure for their re-introduction, although the response is heterogeneous. We aimed to identify the phenotypes, endotypes, and biomarkers of reactions to carboplatin and oxaliplatin and their response to DD. METHODS: Seventy-nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Carboplatin

Share to Cytokines

Share to Desensitization, Immunologic

Share to Drug Hypersensitivity

Share to Hypersensitivity

Share to Oxaliplatin

Source

Open in PubMed

Identifiers

PMID: 37916741
DOI: 10.1111/all.15940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.PMID 37916741Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes and management with desensitization.Semantic proximity Read ↗

From acute phase mediators to drug provocation testing: a single center experience in the allergy work-up of adverse drug reactions to chemotherapySemantic proximity Read ↗

Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization.Semantic proximity Read ↗

Drug hypersensitivity in the fast lane: What clinicians should know about phenotypes, endotypes, and biomarkers.Semantic proximity Read ↗

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.Semantic proximity Read ↗

Management of Hypersensitivity in Oncology Practice: Risk Stratification, Phenotypic Markers, and Desensitization ProtocolsSemantic proximity Read ↗

The Increasing Role of the Allergist in the Management of Infusion Reactions at the Oncology Day HospitalSemantic proximity Read ↗

Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes.Semantic proximity Read ↗

Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms.Semantic proximity Read ↗

Management of adverse reactions to biologic agents.Semantic proximity Read ↗

Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Semantic proximity Read ↗

Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.